---
title: "Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270290059.md"
description: "Soligenix reported positive Phase IIa trial results for SGX945 in treating Behçet's disease, showing reduced ulcers and pain in patients. The study compared SGX945 to apremilast, demonstrating similar efficacy with fewer side effects. Soligenix plans to reformulate SGX945 for home-based treatment and expand its use in other inflammatory conditions. The results were published in Rheumatology, highlighting SGX945's potential as a novel therapeutic."
datetime: "2025-12-19T10:23:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270290059.md)
  - [en](https://longbridge.com/en/news/270290059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270290059.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/270290059.md) | [English](https://longbridge.com/en/news/270290059.md)


# Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease

Seven of eight patients reported perceived benefits such as reduced duration and number of ulcers, and reduced pain. Credit: PreciousJ / Shutterstock.com.

Soligenix has reported positive data from its Phase IIa trial of SGX945 (dusquetide) for the treatment of Behçet’s disease.

The proof-of-concept study examined SGX945 for treating oral ulcers in the illness.

It reported that seven of eight patients experienced beneficial effects over four weeks of treatment, with potential enduring benefits observed during the subsequent four-week follow-up.

Free Sample

### Download sample pages of selected reports

Explore a selection of report samples we have handpicked for you. Get a preview of the insights inside. Download your free copy today.

The open-label study used the Phase III trial of apremilast (Otezla) as a baseline.

It indicated that SGX945’s outcomes in terms of area under the curve (AUC), average oral ulcers, and pain improvement were comparable.

Outcomes from weeks five to eight remained comparable, even though apremilast dosing continued throughout this interval while SGX945 was discontinued after week four in accordance with the study protocol.

Using the primary endpoint from the Phase III apremilast study, the AUC of the mean ulcer number versus time, SGX945 demonstrated a 40% improvement over placebo after four weeks, compared to 37% for apremilast.

This effect was sustained at 32% at week eight, despite SGX945 discontinuation at week four, while apremilast had 41% improvement at week eight.

SGX945 was found to be well-tolerated with no treatment-related adverse events, while apremilast was associated with headache, diarrhoea, and nausea.

These results were published in _Rheumatology_ via _Oxford Academic_, in an article entitled ‘Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers Associated with Behçet Syndrome’.

Soligenix president and CEO Christopher Schaber said: “We are pleased to publish the data from our recent SGX945 Phase IIa trial in aphthous ulcers of Behçet’s disease, enabling the medical community to evaluate this novel mechanism and therapeutic.

“With these, now published, results, we intend to embark on a reformulation of SGX945 to enable home-based treatment, using subcutaneous injection as used, for example, with weight-loss drugs.

“We are excited to expand dusquetide’s development into different innate immune-related inflammatory conditions, such as Behçet’s disease, as a component of our long-term strategy to enhance the value of this unique compound.”

In December 2024, Soligenix started enrolling subjects in its double-blind, multi-centre Phase III trial of HyBryte (synthetic hypericin), a first-in-class photodynamic therapy for cutaneous T-cell lymphoma (CTCL).

### Unlock up to 35% savings on GlobalData reports

Use the code at checkout in the report store

-   ### 20% OFF
    
    Buy 2 reports
    
    Use code:
    
    #### Bundle20
    
-   ### 25% OFF
    
    Buy 3 reports
    
    Use code:
    
    #### Bundle25
    
-   ### 30% OFF
    
    Buy 4 reports
    
    Use code:
    
    #### Bundle30
    
-   ### 35% OFF
    
    Buy 5+ reports
    
    Use code:
    
    #### Bundle35
    

Valid on all reports priced $995 and above. Cannot be combined with other offers.

#### Still deciding what will work best for your business?

Ask our experts for help.

Enquire before buying

### 相關股票

- [Soligenix (SNGX.US)](https://longbridge.com/zh-HK/quote/SNGX.US.md)

## 相關資訊與研究

- [Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation](https://longbridge.com/zh-HK/news/271950396.md)
- [<![CDATA[Andrew Hall: The Discipline of Conviction]]>](https://longbridge.com/zh-HK/news/279076575.md)
- [ADHD May Not Be A Disorder After All](https://longbridge.com/zh-HK/news/278647785.md)
- [ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B](https://longbridge.com/zh-HK/news/278816969.md)
- [Cadrenal Highlights CAD-1005 Preclinical Data in Metabolic Disease](https://longbridge.com/zh-HK/news/278886449.md)